Lymphocytosis
This guideline applies to adults
Introduction
Lymphocytosis is a common finding. Causes may include acute viral, bacterial (eg pertussis) or protozoal (eg toxoplasmosis) infection. Viral infection usually causes a modest and temporary (<2 months) rise in lymphocytes.
Other causes include malignancy (most commonly CLL), other low grade lymphoproliferative disorders, and smoking.
Less common causes include auto-immune disease, medication and stress (eg extreme exercise, cardiac or trauma, previous splenectomy and obesity).
In scope
- Lymphocytosis
Not in scope
- Other haematological conditions
Red Flag Features
-
Features of an acute leukaemia on blood film
- B symptoms (eg involuntary weight loss, night sweats)
*This list is non exhaustive
Investigations required prior to referral
Consider reactive causes.
Following initial detection of lymphocytosis, in an otherwise well patient with no red flags or reactive causes, repeat FBC in 2-3 months time. If lymphocytosis persists, examine for lymphadenopathy and splenomegaly.
If the patient is unwell, request a blood film and consider testing for EBV, CMV and HIV serology for IgM and IgG antibodies
NB. The EBV screen (Monospot or Paul Bunnell) gives both false positive and false negative results and requesting serology for IgG and IgM antibody is preferable and specific.
Management optimisation
Treat and manage any underlying acute infection as appropriate.
CLL is the most common cause of malignant lymphocytosis. Asymptomatic CLL does not benefit from early treatment. Lymphocytosis without symptoms or a known cause can reasonably be monitored in the community with a second FBC after 2 months and then annually.
Encourage smoking cessation as appropriate.
Advice and Guidance
Haematology A&G can be accessed via ERS: Haematology Advice & Guidance
This service should not be used for suspected fast track referrals.
Referral
Emergency referral criteria
If a blood film suggests an acute leukaemia arrange an immediate admission via the medical team.
Urgent referral criteria
CLL is not usually an indication for an urgent fast track referral but seek haematology advice is the patient is significantly unwell (for example if there are new or significant B symptoms, or rapidly enlarging lymph nodes). Haematology advice and guidance is answered within 24 hours, but depending on clinical judgement if the patient is too unwell to wait for this, consider admission via the medical admissions team.
Routine referral criteria
Refer routinely to Haematology if lymphocytosis and:
- Significant and persistent (> 4 weeks) lymphadenopathy in the absence of a secondary cause
- Splenomegaly
- Systemic symptoms
- Unexplained anaemia (Hb <100g/L) or thrombocytopenia (Platelets < 100)
- Progressive lymphocytosis with an increase of ≥50% over a 3-month period or lymphocyte doubling time of <6 months (patients with a lymphocyte count < 30 may require a longer observation period to determine doubling time).
Known CLL
If CLL is being monitored in the community already then referral or discussion with haematology is indicated if:
- the lymphocyte count is rising rapidly e.g. an increase of ≥50% over a 2-month period or lymphocyte doubling time of <6 months (NB. patients with a lymphocyte count < 30 may require a longer observation period to determine doubling time).
- the patient is systemically unwell (eg involuntary weight loss, night sweats)
- clinically significant and persistent lymphadenopathy
- clinically palpable splenomegaly
- other components of the blood count are abnormal (eg anaemia, thrombocytopenia)
Supporting Information
For professionals
For patients
- http://bloodwise.org.uk/info-support/chronic-lymphocytic-leukaemia/
- http://www.macmillan.org.uk/information-and-support/leukaemia/chronic-lymphocytic
References
- Peninsula Cancer Alliance, Haematology Site Specific Group, Advice and Guidance for non-haematological conditions, October 2024
Page Review Information
Review date |
08 July 2025 |
Next review date |
08 July 2027 |
Clinical editor |
Dr L Lomas, RMS GP |
Contributors |
Peninsula Cancer Alliance, Haematology Site Specific Group Dr Michelle Furtado
|